Latest News

Tiziana announces financial results for year ending 31 December 2018

04 April 2019

Tiziana today announces its financial results for the year ended 31 December 2018.

Read more

Tiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH

20 March 2019

Tiziana announced that it has submitted* an Investigational New Drug application ("IND") to the U.S. Food and Drug Administration (FDA)

Read more

Directorate Change

07 February 2019

Tiziana today announces that Riccardo Dalla-Favera MD has resigned from his role as Non-Executive Director of the Company. The Company is grateful to Dr Favera for his time, expertise and commitment to the Company.

Read more

Exercise of Warrants & Issue of Equity

11 December 2018

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR
THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

Tiziana Life Sciences plc

("Tiziana" or the "Company")

Exercise of Warrants & Issue of Equity

New York/London, 11 December 2018 - Tiziana Life Sciences plc (Nasdaq: TLSA...

Read more

Tiziana Completes Patient Enrollment in a Phase 2a Trial to Evaluate Tolerability and Anti-Tumor Activity of Milciclib in Hepatocellular Carcinoma (HCC)

03 December 2018

New York/London, 3 December 2018 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that patient enrollment in the ongoing Phase...

Read more

Tiziana Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human Anti-Cluster Definition 3 Monoclonal Antibody (anti-CD3 mAb), in Healthy Volunteers

28 November 2018

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR
THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

Tiziana Life Sciences plc
(“Tiziana” or the “Company”)

Tiziana Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human Anti-Cluster Definition 3 Monoclonal...

Read more

Page 2 of 4 Previous Next